Novartis (NYSE:NVS) has reportedly agreed to pay $245 million to resolve a class-action litigation. This lawsuit accused the Swiss drugmaker of making an attempt to delay the launch of its low-cost hypertension drug within the U.S.
A licensing settlement signed between Novartis and Par Pharmaceutical again in 2011 was the rationale behind this litigation. Each corporations have been accused of getting into an unlawful “reverse fee” settlement with a view to deliberately delay the introduction of Exforge.
Furthermore, the plaintiffs mentioned that Novartis and Par averted competing with one another. On this entrance, Novartis allowed Par a 180-day exclusivity interval by not launching its Exforge generic available in the market. Equally, Par agreed to not launch its generic drug for about two years after considered one of Novartis’ patents expired.
Novartis’ emphasis on streamlining its operations, together with plans to broaden its presence in Germany and the U.S., bode nicely for long-term development. Additionally, constructive progress in securing regulatory approvals and encouraging trial results may preserve supporting the corporate’s efficiency.
Moreover, the inventory appears to be undervalued. NVS stock has a P/E ratio of 9.3x at current, reflecting a 62.4% low cost from the sector’s median of 24.9. Shares of Novartis have gained greater than 20% over the previous three months.
Particular end-of-year provide: Entry TipRanks Premium instruments for an all-time low worth! Click to learn more.